PERSPECTIVE
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Genetics of Complex Diseases |
|---|
Two types of statistical methods have been widely employed to attempt to identify genetic determinants of complex diseases
linkage analysis and association studies. Linkage analysis methods attempt to identify a region of the
genome that is transmitted within families along with the
disease phenotype of interest. Linkage analysis has been
extremely useful in the identification of genes responsible
for diseases with simple Mendelian inheritance, such as cystic fibrosis (6). The application of linkage analysis to complex disorders without obvious Mendelian inheritance has been much less successful because complex diseases are
most likely influenced by genetic heterogeneity (multiple
genetic causes leading to the same disease), environmental
phenocopies (purely environmental forms of the disease),
incomplete penetrance (subjects inheriting a disease gene
but not developing the disease), genotype-by-environment interactions (nonadditivity of genetic and environmental influences on disease development), and multilocus effects
(more than one gene influences disease development) (7).
Despite these difficulties, multiple regions of the genome
have been recurrently identified by linkage analysis as likely
to contain asthma susceptibility genes. For sarcoidosis,
linked regions have not yet been identified.
Two general approaches have been used to investigate the molecular genetics of complex diseases: candidate gene approaches and whole genome screens followed by positional cloning attempts. Candidate gene approaches can utilize either linkage analysis of highly polymorphic, short tandem repeat marker loci in the candidate region, or association of (usually bi-allelic) coding or noncoding polymorphisms within candidate genes.
| |
Association Analysis: Basic Principles |
|---|
Historically, association analysis of genetic polymorphisms has been mostly performed in a case-control setting with unrelated affected subjects compared with unrelated unaffected subjects. Significant differences in allele frequencies between cases and controls are taken as evidence for involvement of an allele in disease susceptibility. Alternatively, genotype frequencies rather than allele frequencies can be compared in cases and controls.
In practical terms, an observed statistical association between an allele and a phenotypic trait will be the result of one of three situations: (1) the finding could be due to chance or artifact, e.g., confounding or selection bias; (2) the allele is in linkage disequilibrium with an allele at another locus that directly affects the expression of the phenotype; or (3) the allele itself is functional and directly affects the expression of the phenotype.
The biologic principle underlying the association analysis of polymorphisms not directly involved in disease pathogenesis is that of linkage disequilibrium (the second situation listed above). Linkage disequilibrium arises from an increased frequency of particular haplotypes across a population on account of the cosegregation of alleles at closely linked loci. Haplotypes having a greater frequency than would be expected because of random association may arise by population admixture, natural selection, genetic drift, or new mutation combined with population "bottlenecks" (8).
One limitation of linkage analysis is the difficulty of fine mapping the location of a gene influencing a complex disorder. There are not usually enough meioses within 1 to 2 megabases of the disease gene to detect recombination events; moreover, with the effects of phenocopies and genetic heterogeneity in complex diseases, critical recombination events may not be identified with certainty. Association analyses are thus essential for localizing susceptibility loci, and they are intrinsically more powerful than linkage analyses in detecting weak genetic effects (2). However, the characteristics of complex diseases, which are problematic in linkage analysis, including genetic heterogeneity, phenocopies, incomplete penetrance, genotype-by-environment interaction, and multilocus effects, also limit the power of association studies.
Risch and Merikangas have shown that association studies can be a very powerful approach for finding genetic determinants of a complex disorder (9). They suggested that if hundreds of thousands of single nucleotide polymorphisms (SNPs) were identified across the genome, then it would be possible to perform genome-wide association studies to identify the regions of linkage disequilibrium around disease susceptibility genes. In addition, they noted that much smaller sample sizes would be required to detect association than to detect linkage. The SNP Consortium is rapidly identifying single nucleotide polymorphisms, and within the next several years, genome-wide association studies may become a reality.
| |
Factors Complicating Candidate Gene Association Studies |
|---|
The choice of phenotype is critical to the success of gene discovery programs. Most case-control association studies employ a dichotomous variable (affected/unaffected). If the cases include a heterogeneous collection of etiologies for a complex disease, the power to detect a significant association will be reduced. Similarly, if the control group includes subjects who are affected but undiagnosed, power will be reduced. Disease-associated quantitative traits (also termed intermediate phenotypes) have often been used as proxy disease phenotypes in molecular genetic investigations of complex diseases such as asthma (10). In general, continuous phenotype measurements are inherently more informative, objective, and statistically powerful than binary categorizations of disease status, and they avoid the problems of arbitrary dichotomization. Although intermediate phenotypes have been widely used in genetic studies of asthma (e.g., immunoglobulin E and bronchial hyperresponsiveness), such intermediate phenotypes have not been extensively investigated in genetic studies of sarcoidosis.
What are the causes of a spurious association in a case-control study? As in any statistical test, there could be a
false-positive result due to chance; this is less likely if a
very stringent threshold for significance (a low P value) is
met. But how stringent should this threshold be? In linkage analysis, careful consideration has been given to the
appropriate threshold of significance in a genome-wide
screen because adjacent markers do not represent independent tests (11). Similar thresholds have not been determined for association studies, and the appropriate correction for multiple statistical comparisons (multiple markers
and multiple alleles at each marker) remains unclear.
Risch and Merikangas suggested that a Bonferroni correction could be applied if one million SNPs were typed
across the genome, with a P value of 5 × 10
8 required to
demonstrate a significant association (9). However, the
appropriate method of correction for multiple comparisons in candidate gene association studies remains unclear.
Bailey-Wilson and colleagues discussed several possible
Bonferroni corrections for genetic association studies, including the total number of alleles at all loci, the number
of independent alleles at all loci, and the number of loci
(12).
The case-control association study design is also susceptible to spurious associations purely related to differences in population stratification between cases and controls (13). Population stratification, also known as population substructure, can result from recent population admixture or differences in ethnicity between cases and controls (14). Although it is unclear whether population stratification is a frequent problem in case-control association studies, population stratification may be a particular problem in genetically diverse populations such as those of the United States. Therefore, family-based association strategies with analytical methods (such as the transmission/disequilibrium [TDT] test) that avoid spurious associations related to population stratification have become increasingly common in genetic studies of complex diseases (13, 15). A limitation of adult-onset diseases, such as sarcoidosis and COPD, is that it is very difficult to obtain data from parents of adult cases, making traditional TDT studies difficult to perform. One possible solution to this problem is to use family-based association methods that use affected and unaffected siblings (e.g., sib-TDT, sibship disequilibrium test) rather than parent-child data (16, 17). A recently developed approach to assess population stratification in a case-control study is to genotype a set of polymorphic markers unlinked to any candidate loci for the disease of interest in cases and controls (18). Absence of association to these unlinked markers provides some assurance that an association with a candidate locus in those cases and controls is not a spurious result.
| |
Evaluating Case-Control Genetic Association Studies |
|---|
What criteria can be employed to evaluate a case-control
genetic association study? The following general guidelines, summarized in Table 1, may be useful. We will
present these guidelines and apply them to the paper by
Maliarik and colleagues. First, are the candidate gene(s)
under study biologically reasonable? Several factors can
determine the appropriateness of a candidate gene. If human genetic linkage studies have identified a chromosomal region linked to a disease, or if an animal model for
a disease is influenced by a particular gene or syntenic
chromosomal region, positional candidate genes in such
genomic regions warrant strong consideration. In addition,
the biologic plausibility of a candidate gene for involvement in disease pathogenesis is important. However, obvious limitations of this candidate approach are the large
number of potential candidate genes for complex diseases
and the reality that only known genes can be investigated.
Although candidate genes can be selected for study on this
basis, they should not be ruled out on the basis of our current understanding of disease pathophysiology
important new insights may be missed if potential candidate
genes must fit into current pathophysiologic models. Although linked regions have not been identified for sarcoidosis, Maliarik and colleagues discuss the biologic rationale for NRAMP1 as a candidate gene for sarcoidosis.
|
A second criterion in evaluation of case-control association studies is the careful selection of cases and control subjects. Do the case subjects meet appropriate criteria for disease affection? Are control subjects free from symptoms of disease, associated intermediate phenotypes, and potential confounders? Have control subjects been exposed to relevant environmental influences involved in disease pathogenesis while remaining clearly unaffected (19)? Were the cases and controls matched on demographic and environmental factors? Was consideration of population stratification included, either by attempting to match ethnicity or by typing unlinked markers, as suggested by Pritchard and colleagues (18)? Maliarik and colleagues do not explicitly discuss population stratification, but they have matched on racial group. Moreover, they use strict diagnostic criteria for defining affection with sarcoidosis, including tissue biopsy confirmation.
A third criterion in the evaluation of case-control studies is assessment of Hardy-Weinberg equilibrium in the markers studied within the control group. Hardy-Weinberg equilibrium indicates that the genotype frequencies can be determined directly from the allele frequencies; failure to demonstrate Hardy-Weinberg equilibrium could result from genotyping errors, inbreeding, genetic drift, mutation, or population substructure (20). Hardy-Weinberg equilibrium can be readily assessed with a goodness-of-fit chi square test for biallelic markers; for markers with multiple alleles (such as short-tandem repeat markers), more accurate determination of Hardy-Weinberg equilibrium can be obtained with Markov Chain Monte Carlo methods (21). Significant deviations from the expected proportions of homozygote and heterozygote classes in a population of case subjects may be caused by association with the disease allele. Lack of consistency with Hardy-Weinberg equilibrium among control subjects should prompt investigation for potential complications, including genotyping errors and population stratification. Although Hardy-Weinberg calculations are not presented by Maliarik and colleagues, goodness-of-fit tests using the data from their Table 2 (see page 674 of this issue) reveal that the control group is in Hardy-Weinberg equilibrium for the loci presented.
A final criterion for evaluation of a case-control study is correction for multiple comparisons. This remains a problematic topic requiring additional statistical genetic research. However, an effort to correct for spurious associations, which can result from testing a large number of alleles, is warranted. The multiple comparison issue is especially problematic with markers that have multiple alleles like short-tandem repeat polymorphisms; the conservative Bonferroni approach is to use a corrected significance value calculated by multiplication of the observed P value by the number of alleles tested. Bonferroni corrections for the total number of alleles at all loci are probably too conservative (12) because the alleles at one locus are not independent of each other and closely linked loci are probably not independent either. A less conservative but more computationally intensive approach is to estimate empirical significance values using simulation approaches (22). The issue of multiple comparisons is not explicitly addressed by Maliarik and colleagues.
| |
Conclusions |
|---|
Have Maliarik and colleagues identified an important genetic determinant of sarcoidosis? Maybe. In complex disease genetics, replication is especially critical. Further studies to replicate their findings are required. As the number of case-control association studies in complex disease genetics increases, a central repository for such studies would be quite beneficial to avoid any publication bias in favor of positive results. If a case-control association has been consistently replicated, the most optimistic outcome is that a narrow genomic region will have been identified that contains a disease susceptibility gene. Analysis of adjacent markers in haplotypes can be especially helpful at this stage, and family-based association studies are quite useful for haplotype analysis. Ultimately, geneticists will need to turn the problem of complex disease gene identification back over to the molecular and cell biologists because the identification of the functional disease mutation within a set of adjacent genetic variants in tight linkage disequilibrium depends upon the demonstration of a biologic basis for one or more of the putative genetic variants in the development of disease. The role of a putative disease gene variant can only be confirmed after a biologically functional effect has been demonstrated (23).
| |
Footnotes |
|---|
Abbreviations: single nucleotide polymorphisms, SNPs; transmission/disequilibrium test, TDT.
(Received in original form April 7, 2000).
Acknowledgments: The authors would like to thank Dr. Scott Weiss and Dr. Jeffrey Drazen for helpful comments. E.K.S. is supported by an NIH grant (R01 HL61575) and a Research Grant from the American Lung Association. L.J.P. is a National Health and Medical Research Council of Australia (NH and MRC) Research Fellow in Genetic Epidemiology, a Winston Churchill Memorial Trust Churchill Fellow, and an Australian-American Educational Foundation Fulbright Fellow.
| |
References |
|---|
1. Rybicki, B. A., M. J. Maliarik, M. Major, J. Popovich Jr., and M. C. Iannuzzi. 1998. Epidemiology, demographics, and genetics of sarcoidosis. Semin. Respir. Infect. 13: 166-173 [Medline].
2. Elston, R.. 1995. The genetic dissection of multifactorial traits. Clin. Exp. Allergy 2: 103-106 .
3. Sandford, A., T. Weir, and P. Pare. 1996. The genetics of asthma. Am. J. Respir. Crit. Care Med. 153: 1749-1765 [Abstract].
4. Silverman, E. K., and F. E. Speizer. 1996. Risk factors for the development of chronic obstructive pulmonary disease. Med. Clin. North Am. 80: 501-522 [Medline].
5. Masood, E.. 1999. As consortium plans free SNP map of human genome [news]. Nature 398: 545-546 [Medline].
6.
Rommens, J. M.,
M. C. Iannuzzi,
B.-S. Kerem,
M. L. Drumm,
G. Melmer,
M. Dean,
R. Rozmahel,
J. L. Cole,
D. Kennedy,
N. Hidaka,
M. Zsiga,
M. Buchwald,
J. R. Riordan,
L.-C. Tsui, and
F. S. Collins.
1989.
Identification
of the cystic fibrosis gene: chromosome walking and jumping.
Science
245:
1059-1065
7.
Lander, E. S., and
N. J. Schork.
1994.
Genetic dissection of complex traits.
Science
265:
2037-2048
8. Weeks, D. E., and G. M. Lathrop. 1995. Polygenic disease: methods for mapping complex disease traits. Trends Genet. 11: 513-519 [Medline].
9.
Risch, N., and
K. Merikangas.
1996.
The future of genetic studies of complex human diseases.
Science
273:
1516-1517
10. Cookson, W., and L. Palmer. 1998. Investigating the asthma phenotype. Clin. Exp. Allergy 28(Suppl. 1):88-89.
11. Lander, E., and L. Kruglyak. 1995. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat. Gen. 11: 241-247 .
12. Bailey-Wilson, J. E., B. Sorant, A. J. Sorant, C. M. Paul, and R. C. Elston. 1995. Model-free association analysis of a rare disease. Genet. Epidemiol. 12: 571-575 [Medline].
13. Spielman, R. S., R. E. McGinnis, and W. J. Ewens. 1993. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am. J. Hum. Genet. 52: 506-516 [Medline].
14. Ewens, W., and R. Spielman. 1995. The transmission/disequilibrium test: history, subdivision, and admixture. Am. J. Hum. Genet. 57: 455-464 [Medline].
15. Schaid, D. J.. 1998. Statistical genetics 98: transmission disequilibrium, family controls, and great expectations. Am. J. Hum. Genet. 63: 935-941 [Medline].
16. Spielman, R. S., and W. J. Ewens. 1998. A sibship test for linkage in the presence of association: the sib transmission/disequilibrium test. Am. J. Hum. Genet. 62: 450-458 [Medline].
17. Horvath, S., and N. M. Laird. 1998. A discordant-sibship test for disequilibrium and linkage: no need for parental data [see Comments]. Am. J. Hum. Genet. 63: 1886-1897 [Medline].
18. Pritchard, J. K., and N. A. Rosenberg. 1999. Use of unlinked genetic markers to detect population stratification in association studies. Am. J. Hum. Genet. 65: 220-228 [Medline].
19.
Morton, N. E., and
A. Collins.
1998.
Tests and estimates of allelic association in complex inheritance.
Proc. Natl. Acad. Sci. USA
95:
11389-11393
20. Gillespie, J. H. 1998. Population Genetics: A Concise Guide. The Johns Hopkins University Press, Baltimore, MD.
21. Guo, S. W., and E. A. Thompson. 1992. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 48: 361-372 [Medline].
22.
Besag, J., and
P. Clifford.
1991.
Sequential Monte Carlo p-values.
Biometrika
78:
301-304
23. Fields, S.. 1997. The future is function. Nat. Genet. 15: 325-327 [Medline].
This article has been cited by other articles:
![]() |
A. J. Rogers, B. A. Raby, J. A. Lasky-Su, A. Murphy, R. Lazarus, B. J. Klanderman, J. S. Sylvia, J. P. Ziniti, C. Lange, J. C. Celedon, et al. Assessing the Reproducibility of Asthma Candidate Gene Associations, Using Genome-wide Data Am. J. Respir. Crit. Care Med., June 15, 2009; 179(12): 1084 - 1090. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zhu, ICGN Investigators, A. Gulsvik, P. Bakke, S. Ghatta, W. Anderson, D. A. Lomas, E. K. Silverman, and S. G. Pillai Association of TRPV4 gene polymorphisms with chronic obstructive pulmonary disease Hum. Mol. Genet., June 1, 2009; 18(11): 2053 - 2062. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Gao and K. C. Barnes Recent advances in genetic predisposition to clinical acute lung injury Am J Physiol Lung Cell Mol Physiol, May 1, 2009; 296(5): L713 - L725. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. V. Scirica and J. C. Celedon Genetics of Asthma: Potential Implications for Reducing Asthma Disparities Chest, November 1, 2007; 132(5_suppl): 770S - 781S. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zhu, L. Warren, J. Aponte, A. Gulsvik, P. Bakke, The International COPD Genetics Network (ICGN) Inv, W. H. Anderson, D. A. Lomas, E. K. Silverman, and S. G. Pillai The SERPINE2 Gene Is Associated with Chronic Obstructive Pulmonary Disease in Two Large Populations Am. J. Respir. Crit. Care Med., July 15, 2007; 176(2): 167 - 173. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. DeMeo, C. P. Hersh, E. A. Hoffman, A. A. Litonjua, R. Lazarus, D. Sparrow, J. O. Benditt, G. Criner, B. Make, F. J. Martinez, et al. Genetic Determinants of Emphysema Distribution in the National Emphysema Treatment Trial Am. J. Respir. Crit. Care Med., July 1, 2007; 176(1): 42 - 48. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Meyer and J. G. N. Garcia Wading into the Genomic Pool to Unravel Acute Lung Injury Genetics Proceedings of the ATS, January 1, 2007; 4(1): 69 - 76. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. K. Silverman Progress in chronic obstructive pulmonary disease genetics. Proceedings of the ATS, July 1, 2006; 3(5): 405 - 408. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Hersh, D. L. DeMeo, C. Lange, A. A. Litonjua, J. J. Reilly, D. Kwiatkowski, N. Laird, J. S. Sylvia, D. Sparrow, F. E. Speizer, et al. Attempted Replication of Reported Chronic Obstructive Pulmonary Disease Candidate Gene Associations Am. J. Respir. Cell Mol. Biol., July 1, 2005; 33(1): 71 - 78. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. S. Chang, J. S. Kim, J. H. Lee, J. I. Cho, T. Y. Rhim, S.-T. Uh, B. L. Park, I. Y. Chung, C.-S. Park, and H. D. Shin A Single Nucleotide Polymorphism on the Promoter of eotaxin1 Associates with Its mRNA Expression and Asthma Phenotypes J. Immunol., February 1, 2005; 174(3): 1525 - 1531. [Abstract] [Full Text] [PDF] |
||||
![]() |
C P Hersh, M Dahl, N P Ly, C S Berkey, B G Nordestgaard, and E K Silverman Chronic obstructive pulmonary disease in {alpha}1-antitrypsin PI MZ heterozygotes: a meta-analysis Thorax, October 1, 2004; 59(10): 843 - 849. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J Palmer The New Epidemiology: putting the pieces together in complex disease aetiology Int. J. Epidemiol., October 1, 2004; 33(5): 925 - 928. [Full Text] [PDF] |
||||
![]() |
R. Lazarus, B. A. Raby, C. Lange, E. K. Silverman, D. J. Kwiatkowski, D. Vercelli, W. J. Klimecki, F. D. Martinez, and S. T. Weiss TOLL-like Receptor 10 Genetic Variation Is Associated with Asthma in Two Independent Samples Am. J. Respir. Crit. Care Med., September 15, 2004; 170(6): 594 - 600. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Whitsett, C. J. Bachurski, K. C. Barnes, P. A. Bunn Jr., L. M. Case, D. N. Cook, D. Crooks, M. W. Duncan, L. Dwyer-Nield, R. C. Elston, et al. Functional Genomics of Lung Disease Am. J. Respir. Cell Mol. Biol., August 1, 2004; 31(2/S1): S1 - S81. [Full Text] [PDF] |
||||
![]() |
A E Hegab, T Sakamoto, Y Uchida, A Nomura, Y Ishii, Y Morishima, M Mochizuki, T Kimura, W Saitoh, H H Massoud, et al. CLCA1 gene polymorphisms in chronic obstructive pulmonary disease J. Med. Genet., March 1, 2004; 41(3): e27 - 27. [Full Text] [PDF] |
||||
![]() |
E. S. Silverman, L. J. Palmer, V. Subramaniam, A. Hallock, S. Mathew, J. Vallone, D. S. Faffe, T. Shikanai, B. A. Raby, S. T. Weiss, et al. Transforming Growth Factor-{beta}1 Promoter Polymorphism C-509T Is Associated with Asthma Am. J. Respir. Crit. Care Med., January 15, 2004; 169(2): 214 - 219. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. N. Gong, Z. Wei, L.-L. Xu, D. P. Miller, B. T. Thompson, and D. C. Christiani Polymorphism in the Surfactant Protein-B Gene, Gender, and the Risk of Direct Pulmonary Injury and ARDS Chest, January 1, 2004; 125(1): 203 - 211. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zorzetto, I. Ferrarotti, R. Trisolini, L. L. Agli, R. Scabini, M. Novo, A. De Silvestri, M. Patelli, M. Martinetti, M. Cuccia, et al. Complement Receptor 1 Gene Polymorphisms Are Associated with Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., August 1, 2003; 168(3): 330 - 334. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Ferrarotti, M. Zorzetto, M. Beccaria, L.S. Gile, R. Porta, N. Ambrosino, P.F. Pignatti, I. Cerveri, E. Pozzi, and M. Luisetti Tumour necrosis factor family genes in a phenotype of COPD associated with emphysema Eur. Respir. J., March 1, 2003; 21(3): 444 - 449. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Baron, L. J. Palmer, K. Tantisira, S. Gabriel, L. A. Sonna, L. Le, A. Hallock, T. A. Libermann, J. M. Drazen, S. T. Weiss, et al. DNA Sequence Variants in Epithelium-Specific ETS-2 and ETS-3 Are Not Associated with Asthma Am. J. Respir. Crit. Care Med., October 1, 2002; 166(7): 927 - 932. [Abstract] [Full Text] |
||||
![]() |
M. C. Iannuzzi, M. Maliarik, and B. A. Rybicki Nomination of a Candidate Susceptibility Gene in Sarcoidosis . The Complement Receptor 1 Gene Am. J. Respir. Cell Mol. Biol., July 1, 2002; 27(1): 3 - 7. [Full Text] [PDF] |
||||
![]() |
M. Zorzetto, C. Bombieri, I. Ferrarotti, S. Medaglia, C. Agostini, C. Tinelli, G. Malerba, N. Carrabino, A. Beretta, L. Casali, et al. Complement Receptor 1 Gene Polymorphisms in Sarcoidosis Am. J. Respir. Cell Mol. Biol., July 1, 2002; 27(1): 17 - 23. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Palmer, E. S. Silverman, S. T. Weiss, and J. M. Drazen Pharmacogenetics of Asthma Am. J. Respir. Crit. Care Med., April 1, 2002; 165(7): 861 - 866. [Full Text] [PDF] |
||||
![]() |
E. K. Silverman Genetic Epidemiology of COPD Chest, March 1, 2002; 121(2007): 1S - 6S. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. du Bois The Genetic Predisposition to Interstitial Lung Disease : Functional Relevance Chest, March 1, 2002; 121(2007): 14S - 20S. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Weiss Association Studies in Asthma Genetics Am. J. Respir. Crit. Care Med., December 1, 2001; 164(11): 2014 - 2015. [Full Text] [PDF] |
||||
![]() |
R. M. du Bois Sarcoidosis: Do Our Genes Really Matter? Am. J. Respir. Crit. Care Med., September 1, 2001; 164(5): 725 - 726. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Proc. Am. Thorac. Soc. | Am. J. Respir. Crit. Care Med. |